Search Results for "vol"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vol. Results 421 to 426 of 426 total matches.

Prenatal Acetaminophen Use and Autism

   
The Medical Letter on Drugs and Therapeutics • Dec 08, 2025  (Issue 1743)
population (100% of tested samples 2 The Medical Letter ® Vol. 67 Published online October 27, 2025 ...
Acetaminophen has been considered the drug of choice for treatment of fever and pain during pregnancy for decades, but a recent announcement by the US Department of Health and Human Services (HHS) has prompted discussion about its effects on fetal neurodevelopment and the risk of autism.
Med Lett Drugs Ther. 2025 Dec 8;67(1743):193-5   doi:10.58347/tml.2025.1743a |  Show IntroductionHide Introduction

Booster Doses of COVID-19 Vaccines

   
The Medical Letter on Drugs and Therapeutics • Nov 29, 2021  (Issue 1638)
October 29, 2021. 188 The Medical Letter ® Vol. 63 (1638) November 29, 2021 8. LR Baden et al. Covid-19 ...
The FDA has expanded the Emergency Use Authorizations (EUAs) for the mRNA-based COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) and the adenovirus-based vaccine manufactured by Johnson & Johnson/Janssen to include administration of a booster dose in select populations after primary immunization with either the same COVID-19 vaccine or a different one.
Med Lett Drugs Ther. 2021 Nov 29;63(1638):186-8 |  Show IntroductionHide Introduction

Two Vaccines (Arexvy and Abrysvo) for Prevention of RSV Disease

   
The Medical Letter on Drugs and Therapeutics • Oct 02, 2023  (Issue 1686)
. The Medical Letter ® Vol. 65 (1686) October 2, 2023 Beyfortus Arexvy Abrysvo nirsevimab palivizumab RSV ...
Two recombinant vaccines, Arexvy (GSK) and Abrysvo (Pfizer), have been approved by the FDA for prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in adults ≥60 years old. They are the first RSV vaccines to be approved in the US. Abrysvo is also approved for use in pregnant women at 32-36 weeks' gestation to prevent LRTD caused by RSV in their infants from birth through 6 months of age.
Med Lett Drugs Ther. 2023 Oct 2;65(1686):153-6   doi:10.58347/tml.2023.1686a |  Show IntroductionHide Introduction

Drugs for Depression

   
The Medical Letter on Drugs and Therapeutics • Dec 11, 2023  (Issue 1691)
.  The Medical Letter® Vol. 65 (1691) symptoms, serotonin syndrome occurs rarely with SSRI monotherapy ...
A selective serotonin reuptake inhibitor (SSRI) is generally used for initial treatment of major depressive disorder (MDD). A serotonin-norepinephrine reuptake inhibitor (SNRI), bupropion (Wellbutrin SR, and others), and mirtazapine (Remeron, and others) are reasonable alternatives. Improvement in symptoms can occur within the first two weeks of treatment with these drugs, but a substantial benefit may not be achieved for 4-8 weeks.
Med Lett Drugs Ther. 2023 Dec 11;65(1691):193-200   doi:10.58347/tml.2023.1691a |  Show IntroductionHide Introduction

Drugs for Epilepsy

   
The Medical Letter on Drugs and Therapeutics • Aug 05, 2024  (Issue 1708)
Vol. 66 (1708) August 5, 2024 Drugs for Epilepsy When used for the appropriate seizure type ...
When used for the appropriate seizure type, antiseizure medications (ASMs) are roughly equivalent in efficacy. In addition to the seizure type, the choice of drug is usually based on factors such as ease of use, spectrum of activity, adverse effects, interactions with other drugs, presence of comorbid conditions, suitability for elderly persons and those with childbearing potential, and cost. Treatment should begin with a single drug, increasing the dosage gradually until seizures are controlled or adverse effects become unacceptable. If seizures persist, expert clinicians generally...
Med Lett Drugs Ther. 2024 Aug 5;66(1708):121-8   doi:10.58347/tml.2024.1708a |  Show IntroductionHide Introduction

Antiviral Drugs for Seasonal Influenza

   
The Medical Letter on Drugs and Therapeutics • Nov 09, 2026  (Issue 1767)
® Vol. 68 (1767) November 9, 2026 FluMist Xofluza baloxavir Relenza zanamivir Rapivab peramivir Tamiflu ...
Influenza is typically a self-limited illness, but complications including pneumonia, respiratory failure, and death can occur, especially in persons at increased risk (see Table 1). Influenza vaccination reduces the incidence of laboratory-confirmed influenza and the risk of complications associated with influenza illness. Annual vaccination should be offered to all persons ≥6 months old as long as influenza viruses are circulating in the community.
Med Lett Drugs Ther. 2026 Nov 9;68(1767):177-81   doi:10.58347/tml.2026.1767a |  Show IntroductionHide Introduction